LLY

1,010.74

+3.11%↑

JNJ

229.56

+1.07%↑

ABBV

214.58

+2.77%↑

UNH

393.5

+1.7%↑

AZN

185.65

+1.27%↑

LLY

1,010.74

+3.11%↑

JNJ

229.56

+1.07%↑

ABBV

214.58

+2.77%↑

UNH

393.5

+1.7%↑

AZN

185.65

+1.27%↑

LLY

1,010.74

+3.11%↑

JNJ

229.56

+1.07%↑

ABBV

214.58

+2.77%↑

UNH

393.5

+1.7%↑

AZN

185.65

+1.27%↑

LLY

1,010.74

+3.11%↑

JNJ

229.56

+1.07%↑

ABBV

214.58

+2.77%↑

UNH

393.5

+1.7%↑

AZN

185.65

+1.27%↑

LLY

1,010.74

+3.11%↑

JNJ

229.56

+1.07%↑

ABBV

214.58

+2.77%↑

UNH

393.5

+1.7%↑

AZN

185.65

+1.27%↑

Kodu・Aktsiate loetelu・Compugen Ltd

Compugen Ltd

Avatud

2.82 -1.05

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.6

Max

2.91

Põhinäitajad
By Trading Economics
Sissetulek	64M 57M
Müük	65M 67M
P/E Sektori keskmine	7.553 51.415
Kasumimarginaal	84.425
Töötajad	75
EBITDA	63M 56M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+69.82% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	60M 271M
Eelmine avamishind	3.87
Eelmine sulgemishind	2.82

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.25 / 1.48 Toetus ja vastupanu

Compugen Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. mai 2026, 23:10 UTC

Kuumad aktsiad

Stocks to Watch: Agilysys, XP

18. mai 2026, 18:44 UTC

Suurimad hinnamuutused turgudel

Claritev Shares Recover After Comments About DOJ

18. mai 2026, 23:55 UTC

Tulu

Review & Preview: Earnings' Last Gasp -- Barrons.com

18. mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18. mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18. mai 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18. mai 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18. mai 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18. mai 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18. mai 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. mai 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

18. mai 2026, 20:25 UTC

Tulu

Correct: XP 1Q Total Client Assets BRL1.53T

18. mai 2026, 20:23 UTC

Tulu

XP 1Q Total Client Assets BRL1.53B

18. mai 2026, 20:19 UTC

Tulu

XP 1Q Adj EPS BRL2.49 >XP

18. mai 2026, 20:19 UTC

Tulu

XP 1Q Rev BRL4.73B >XP

18. mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18. mai 2026, 19:00 UTC

Tulu

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18. mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18. mai 2026, 18:17 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18. mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18. mai 2026, 16:57 UTC

Omandamised, ülevõtmised, äriostud

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18. mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18. mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18. mai 2026, 16:54 UTC

Omandamised, ülevõtmised, äriostud

Vinci Doesn't Set Out Financial Details of Deal

18. mai 2026, 16:50 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18. mai 2026, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18. mai 2026, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18. mai 2026, 16:48 UTC

Omandamised, ülevõtmised, äriostud

Vinci Buys Canada's Modern Group of Companies

Võrdlus sarnastega

Hinnamuutus

Compugen Ltd Prognoos

Hinnasiht

By TipRanks

69.82% tõus

12 kuu keskmine prognoos

Keskmine 4.67 USD 69.82%

Kõrge 6 USD

Madal 4 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Compugen Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Compugen Ltd aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.25 / 1.48Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.